Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study.
NEUROLOGY AND THERAPY（2024）
关键词
Fremanezumab,Migraine treatment,CGRP monoclonal antibody,Real-world,Long-term treatment,Psychiatric comorbidities,Medication overuse,Disability
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要